Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · individuals with moderate to severe disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in clinical worsening: need for invasive mechanical ventilation, or… compared with placebo or standard care alone (high certainty).
1 finding from 1 review
Admission to hospital or death within 28 days · outpatients withmild disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in admission to hospital or death within 28 days compared with placebo or standard care alone (low certainty).
1 finding from 1 review
Resolution of symptoms · outpatients withmild disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to symptom resolution · outpatients withmild disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in time to symptom resolution (absolute effect calculated for day 12) compared with placebo or standard care alone (low certainty).
1 finding from 1 review
Quality of life, · outpatients withmild disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grades 3 and 4 adverse events · outpatients withmild disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in grades 3 and 4 adverse events compared with placebo or standard care alone (low certainty).
1 finding from 1 review
Serious adverse events · outpatients withmild disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in serious adverse events compared with placebo or standard care alone (low certainty).
1 finding from 1 review
Clinical improvement: participants discharged from hospital ‐ not reported · individuals with moderate to severe disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in clinical improvement: participants discharged from hospital compared with placebo or standard care alone (high certainty).
1 finding from 1 review
Quality of life, · individuals with moderate to severe disease
1 finding from 1 review
Grades 3 and 4 adverse events · individuals with moderate to severe disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in grades 3 and 4 adverse events compared with placebo or standard care alone (low certainty).
1 finding from 1 review
Serious adverse events ‐ total · individuals with moderate to severe disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in serious adverse events ‐ total compared with placebo or standard care alone (moderate certainty).
1 finding from 1 review
Clinical remission · people with Crohn's disease
Vedolizumab leads to higher induction of clinical remission (6–10 weeks) compared with placebo (high certainty).
1 finding from 1 review
Induction of clinical response (6–10 weeks) · people with Crohn's disease
Vedolizumab leads to higher induction of clinical response (6–10 weeks) compared with placebo (high certainty).
1 finding from 1 review
Adverse events (6–10 weeks) · people with Crohn's disease
Vedolizumab showed no clear difference in adverse events (6–10 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events (6–10 weeks) · people with Crohn's disease
Vedolizumab showed no clear difference in serious adverse events (6–10 weeks) compared with placebo (low certainty).
1 finding from 1 review
Maintenance of clinical remission · people with Crohn's disease
Vedolizumab leads to higher maintenance of clinical remission (52–60 weeks) compared with placebo (high certainty).
1 finding from 1 review
Adverse events (52–60 weeks) · people with Crohn's disease
Vedolizumab showed no clear difference in adverse events (52–60 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events (52–60 weeks) · people with Crohn's disease
Vedolizumab showed no clear difference in serious adverse events (52–60 weeks) compared with placebo (low certainty).
1 finding from 1 review
eGFR · people with CKD
1 finding from 1 review
Albuminuria or proteinuria · people with CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found